(Q34485381)

2 August 2017

title

A model for the turnover of dihydrotestosterone in the presence of the irreversible 5 alpha-reductase inhibitors GI198745 and finasteride (English)

1 reference

2 August 2017

Gisleskog PO

1

1 reference

2 August 2017

Hermann D

series ordinal

2

1 reference

2 August 2017

Hammarlund-Udenaes M

series ordinal

3

1 reference

2 August 2017

Karlsson MO

series ordinal

4

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 December 1998

1 reference

Clinical Pharmacology & Therapeutics

2 August 2017

published in

1 reference

2 August 2017

volume

64

1 reference

2 August 2017

issue

6

1 reference

2 August 2017

page(s)

636-647

1 reference

Steroid 5 alpha-reductase: two genes/two enzymes

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia. Finasteride Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

The development of human benign prostatic hyperplasia with age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

High prevalence of benign prostatic hypertrophy in the community

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

Is the prostate pill finally here?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

Genetic and pharmacological evidence for more than one human steroid 5 alpha-reductase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

Hormonal effects of an orally active 4-azasteroid inhibitor of 5 alpha-reductase in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

Clinical pharmacokinetics and pharmacodynamics of finasteride

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

Mechanism of Time-Dependent Inhibition of 5.alpha.-Reductases by .DELTA.1-4-Azasteroids: Toward Perfection of Rates of Time-Dependent Inhibition by Using Ligand-Binding Energies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

Finasteride: a slow-binding 5 alpha-reductase inhibitor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

5 alpha-metabolism in finasteride-treated subjects and male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. A review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9236%2898%2990054-6

10.1016/S0009-9236(98)90054-6

7 January 2021

Identifiers

DOI

1 reference

2 August 2017

1 reference